MAAT PHARMA SACA (MAAT.PA) Fundamental Analysis & Valuation

EPA:MAAT • FR0012634822

6.82 EUR
-0.16 (-2.29%)
Last: Mar 6, 2026, 07:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership

This MAAT.PA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to MAAT. MAAT was compared to 75 industry peers in the Biotechnology industry. MAAT has a bad profitability rating. Also its financial health evaluation is rather negative. MAAT is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

0

1. MAAT.PA Profitability Analysis

1.1 Basic Checks

  • MAAT had negative earnings in the past year.
  • In the past year MAAT has reported a negative cash flow from operations.
  • MAAT had negative earnings in each of the past 5 years.
  • MAAT had a negative operating cash flow in each of the past 5 years.
MAAT.PA Yearly Net Income VS EBIT VS OCF VS FCFMAAT.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -5M -10M -15M -20M -25M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -63.60%, MAAT is doing worse than 66.67% of the companies in the same industry.
  • With a Return On Equity value of -374.74%, MAAT is not doing good in the industry: 61.33% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -63.6%
ROE -374.74%
ROIC N/A
ROA(3y)-50.55%
ROA(5y)-38.35%
ROE(3y)-142.38%
ROE(5y)-96.6%
ROIC(3y)N/A
ROIC(5y)N/A
MAAT.PA Yearly ROA, ROE, ROICMAAT.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 0 100 -100 -200 -300

1.3 Margins

  • Looking at the Gross Margin, with a value of 61.68%, MAAT is in line with its industry, outperforming 57.33% of the companies in the same industry.
  • In the last couple of years the Gross Margin of MAAT has declined.
  • MAAT does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 61.68%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-9.66%
GM growth 5YN/A
MAAT.PA Yearly Profit, Operating, Gross MarginsMAAT.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600 -800

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. MAAT.PA Health Analysis

2.1 Basic Checks

  • MAAT does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • MAAT has more shares outstanding than it did 1 year ago.
  • MAAT has more shares outstanding than it did 5 years ago.
  • MAAT has a worse debt/assets ratio than last year.
MAAT.PA Yearly Shares OutstandingMAAT.PA Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M
MAAT.PA Yearly Total Debt VS Total AssetsMAAT.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

2.2 Solvency

  • MAAT has an Altman-Z score of 0.03. This is a bad value and indicates that MAAT is not financially healthy and even has some risk of bankruptcy.
  • MAAT's Altman-Z score of 0.03 is in line compared to the rest of the industry. MAAT outperforms 52.00% of its industry peers.
  • MAAT has a Debt/Equity ratio of 1.43. This is a high value indicating a heavy dependency on external financing.
  • MAAT has a Debt to Equity ratio (1.43) which is in line with its industry peers.
Industry RankSector Rank
Debt/Equity 1.43
Debt/FCF N/A
Altman-Z 0.03
ROIC/WACCN/A
WACC7.56%
MAAT.PA Yearly LT Debt VS Equity VS FCFMAAT.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 20M -20M

2.3 Liquidity

  • A Current Ratio of 2.22 indicates that MAAT has no problem at all paying its short term obligations.
  • MAAT's Current ratio of 2.22 is in line compared to the rest of the industry. MAAT outperforms 49.33% of its industry peers.
  • MAAT has a Quick Ratio of 2.21. This indicates that MAAT is financially healthy and has no problem in meeting its short term obligations.
  • The Quick ratio of MAAT (2.21) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 2.22
Quick Ratio 2.21
MAAT.PA Yearly Current Assets VS Current LiabilitesMAAT.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. MAAT.PA Growth Analysis

3.1 Past

  • MAAT shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -4.65%.
  • The Revenue has grown by 52.55% in the past year. This is a very strong growth!
  • The Revenue has been growing by 49.01% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-4.65%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%7.57%
Revenue 1Y (TTM)52.55%
Revenue growth 3Y49.01%
Revenue growth 5YN/A
Sales Q2Q%41.02%

3.2 Future

  • Based on estimates for the next years, MAAT will show a very negative growth in Earnings Per Share. The EPS will decrease by -17.71% on average per year.
  • The Revenue is expected to grow by 121.67% on average over the next years. This is a very strong growth
EPS Next Y-62.16%
EPS Next 2Y-28.13%
EPS Next 3Y-17.71%
EPS Next 5YN/A
Revenue Next Year258.42%
Revenue Next 2Y101.88%
Revenue Next 3Y78.25%
Revenue Next 5Y121.67%

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
MAAT.PA Yearly Revenue VS EstimatesMAAT.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M
MAAT.PA Yearly EPS VS EstimatesMAAT.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 -1 -2 -3

More info and screens

Find the best growth stocksShow best growing peers

0

4. MAAT.PA Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for MAAT. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for MAAT. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MAAT.PA Price Earnings VS Forward Price EarningsMAAT.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MAAT.PA Per share dataMAAT.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -1 -2 -3

4.3 Compensation for Growth

  • A cheap valuation may be justified as MAAT's earnings are expected to decrease with -17.71% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-28.13%
EPS Next 3Y-17.71%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. MAAT.PA Dividend Analysis

5.1 Amount

  • MAAT does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

MAAT.PA Fundamentals: All Metrics, Ratios and Statistics

MAAT PHARMA SACA

EPA:MAAT (3/6/2026, 7:00:00 PM)

6.82

-0.16 (-2.29%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-26
Earnings (Next)N/A
Inst Owners38.96%
Inst Owner ChangeN/A
Ins Owners1.43%
Ins Owner ChangeN/A
Market Cap128.35M
Revenue(TTM)3.92M
Net Income(TTM)-31.09M
Analysts87.27
Price Target17.27 (153.23%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-4.82%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)-83.81%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-2.76%
Revenue NY rev (3m)36.56%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 32.73
P/FCF N/A
P/OCF N/A
P/B 15.47
P/tB 23.59
EV/EBITDA N/A
EPS(TTM)-2.15
EYN/A
EPS(NY)-3.41
Fwd EYN/A
FCF(TTM)-1.33
FCFYN/A
OCF(TTM)-1.29
OCFYN/A
SpS0.21
BVpS0.44
TBVpS0.29
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -63.6%
ROE -374.74%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 61.68%
FCFM N/A
ROA(3y)-50.55%
ROA(5y)-38.35%
ROE(3y)-142.38%
ROE(5y)-96.6%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-9.66%
GM growth 5YN/A
F-Score2
Asset Turnover0.08
Health
Industry RankSector Rank
Debt/Equity 1.43
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 45.25%
Cap/Sales 19.94%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.22
Quick Ratio 2.21
Altman-Z 0.03
F-Score2
WACC7.56%
ROIC/WACCN/A
Cap/Depr(3y)108.1%
Cap/Depr(5y)117.91%
Cap/Sales(3y)39.59%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-4.65%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%7.57%
EPS Next Y-62.16%
EPS Next 2Y-28.13%
EPS Next 3Y-17.71%
EPS Next 5YN/A
Revenue 1Y (TTM)52.55%
Revenue growth 3Y49.01%
Revenue growth 5YN/A
Sales Q2Q%41.02%
Revenue Next Year258.42%
Revenue Next 2Y101.88%
Revenue Next 3Y78.25%
Revenue Next 5Y121.67%
EBIT growth 1Y-25.97%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year8.62%
EBIT Next 3Y-9.91%
EBIT Next 5YN/A
FCF growth 1Y-27.43%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-31.28%
OCF growth 3YN/A
OCF growth 5YN/A

MAAT PHARMA SACA / MAAT.PA FAQ

What is the ChartMill fundamental rating of MAAT PHARMA SACA (MAAT.PA) stock?

ChartMill assigns a fundamental rating of 2 / 10 to MAAT.PA.


What is the valuation status of MAAT PHARMA SACA (MAAT.PA) stock?

ChartMill assigns a valuation rating of 0 / 10 to MAAT PHARMA SACA (MAAT.PA). This can be considered as Overvalued.


Can you provide the profitability details for MAAT PHARMA SACA?

MAAT PHARMA SACA (MAAT.PA) has a profitability rating of 0 / 10.


Can you provide the expected EPS growth for MAAT stock?

The Earnings per Share (EPS) of MAAT PHARMA SACA (MAAT.PA) is expected to decline by -62.16% in the next year.